Ocular Therapeutix™ Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American
Society of Retina Specialists (ASRS)
Presentation to highlight preclinical data supporting the Company’s proprietary sustained release technology
for intravitreal injections
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of
innovative therapies for diseases and conditions of the eye, today announced that Jonathan Talamo, M.D., Chief Medical Officer,
will present at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS) on Monday, August 8,
2016, in San Francisco, CA.
Dr. Talamo will provide an update on the Company’s ongoing preclinical development programs for its sustained release hydrogel
technology being developed to treat wet age-related macular degeneration (wet AMD) and other retinovascular diseases. The Company
is developing sustained-release hydrogel-based drug delivery depots for intravitreal injection that can be formulated with both
small and large molecule pharmaceuticals, with the goal of delivering sustained and therapeutic levels of drugs to targeted ocular
tissues for 4-6 months.
“We at Ocular Therapeutix continue to be encouraged by the results emerging from work with our proprietary delivery platforms
for high molecular weight protein VEGF inhibitors and small molecule Tyrosine Kinase Inhibitors,” stated Dr. Talamo. “I look
forward to sharing these interesting findings with my colleagues in San Francisco next week.”
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative
therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead
product candidate, DEXTENZA™ (dexamethasone insert), is in Phase 3 clinical development for post-surgical ocular inflammation and
pain and allergic conjunctivitis, and in Phase 2 clinical development for dry eye disease. A third Phase 3 clinical trial is being
conducted for post-surgical ocular inflammation and pain. For glaucoma and ocular hypertension, the Company plans to initiate the
first of two OTX-TP (sustained release travoprost) Phase 3 clinical trials in the third quarter of 2016. Ocular Therapeutix is
evaluating sustained-release injectable drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about
the development and regulatory status of the Company’s product candidates, such as the Company’s expectations and plans regarding
regulatory submissions for and the timing and conduct of clinical trials of DEXTENZA for post-surgical ocular inflammation and
pain, including our expectations regarding the pending NDA filed with the FDA, DEXTENZA™ for the treatment of allergic
conjunctivitis, DEXTENZA for dry eye disease and OTX-TP for the treatment of glaucoma and ocular hypertension, the ongoing
development of the Company’s sustained release hydrogel depot technology and the advancement of the Company's other product
candidates, the potential utility of any of the Company’s product candidates, the sufficiency of the Company’s cash resources and
other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan,"
"predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking
statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future
results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure®
Sealant or any product candidate that receives regulatory approval, the initiation and conduct of clinical trials, availability of
data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific approach and general
development progress, the availability or commercial potential of the Company’s product candidates, the sufficiency of cash
resources and need for additional financing or other actions and other factors discussed in the “Risk Factors” section contained in
the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking
statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates
that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of
this release.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Ocular Therapeutix, Inc.
Scott Corning
Vice President of Sales and Marketing
scorning@ocutx.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160805005093/en/